Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

TKT Replagal Renal Function Trial To Be Submitted By Year-End

Executive Summary

Transkaryotic Therapies will submit data from a Phase III trial evaluating renal function in Fabry disease patients treated with Replagal by the end of the year, CEO Richard Selden, MD/PhD, said Oct. 30
Advertisement

Related Content

CBER’s Long Goodbye: Biologics Approval Time Jumps To 30 Months In 2002
CBER’s Long Goodbye: Biologics Approval Time Jumps To 30 Months In 2002
Replagal Advisory Committee Meeting Possible By End Of The Year, TKT Says
Replagal Advisory Committee Meeting Possible By End Of The Year, TKT Says
Advertisement
UsernamePublicRestriction

Register

PS040747

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel